Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$7.87M$7.87M+100.5% vs Q3 2017 Net Income-$6.15M-$6.15MN/M vs Q3 2017 EPS Diluted-$0.11-$0.11N/M vs Q3 2017 Operating Income-$7,804,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,684,000N/M Margins · derivedOperating margin-99.1%+32.9 pt vs Q3 2017
Net margin-78.2%+101.6 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end